Evidence map›Paper›PMID 40689854›Full record

ArticleThe Journal of experimental medicine2025

Targeting infection-specific peptides in immunopeptidomics studies for vaccine target discovery.

Owen Leddy, Yuko Yuki, Mary Carrington, Bryan D Bryson, Forest M White

Abstract read
In one paragraph

Article in The Journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Discovery immunology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Owen LeddyDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-3437-1956
Yuko YukiBasic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute , Frederick, MD, USA.ORCID 0000-0003-1721-6003
Mary CarringtonRagon Institute of MGH, Harvard, and MIT , Cambridge, MA, USA.ORCID 0000-0002-2692-2180
Bryan D Bryson *Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-1716-6712
Forest M White *Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-1545-1651

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
TRAINING GRANTS IN ENVIROMENTAL TOXICOLOGYT32ES007020 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ESSIGMANN, JOHN M · 1985 to 2024
$13.1M
Quantitative systems biology of glioblastoma cells and their interactions with the neuronal and immunological milieuU54CA283114 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Forest M White · 2023 to 2026
$9.7M
High-dimensional characterization of phagosome composition, control and phagocytic receptor redundancyR35GM142900 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI BRYSON, BRYAN DAVID · 2021 to 2025
$2.1M
Identification of adaptive response mechanisms in breast cancer by information theory and proteomicsU01CA238720 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KRAVCHENKO-BALASHA, NATALY, WHITE, FOREST M · 2019 to 2023
$2.0M
Koch InstituteNCI NIH HHS U01 CA238720NCI NIH HHS U54 CA283114NIAID NIH HHS P30 AI060354NIEHS NIH HHS T32 ES007020NIEHS NIH HHS T32-ES007020NIGMS NIH HHS R35 GM142900NIH HHS 1R35GM142900NIH HHS R01A1022553NIH HHS U01 CA238720NIH HHS U54 CA283114
6 · The paper itself

Abstract

Vaccine-elicited T cell responses can contribute to immune protection against emerging infectious disease risks such as antimicrobial-resistant (AMR) microbial pathogens and viruses with pandemic potential, but rapidly identifying appropriate targets for T cell priming vaccines remains challenging. Mass spectrometry (MS) analysis of peptides presented on MHCs can identify potential targets for protective T cell responses in a proteome-wide manner. However, pathogen-derived peptides are outnumbered by self-peptides in the MHC repertoire and may be missed in untargeted MS analyses. Here, we present a novel approach, termed PathMHC, that uses computational analysis of untargeted MS data followed by targeted MS to discover novel pathogen-derived MHC peptides more efficiently than untargeted methods alone. We applied this workflow to identify MHC peptides derived from multiple microbes, including potential vaccine targets presented on MHC-I by human dendritic cells infected with Mycobacterium tuberculosis (Mtb), finding that all Mtb peptides detected in the MHC-I repertoire derived from proteins exported by type VII secretion systems. PathMHC will facilitate antigen discovery campaigns for vaccine development.

Indexed as

Mycobacterium tuberculosisPeptidesProteomicsVaccinesDendritic CellsHistocompatibility Antigens Class IHumansMass SpectrometryVaccine DevelopmentHistocompatibility Antigens Class IPeptidesVaccines

Identifiers

PMID40689854
PMCPMC12279011

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.